Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)

Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antibody, in J...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Dermatol
Main Authors: Saeki, Hidehisa, Nakagawa, Hidemi, Nakajo, Ko, Ishii, Taeko, Morisaki, Yoji, Aoki, Takehiro, Cameron, Gregory S., Osuntokun, Olawale O., Akasaka, Toshihide, Asano, Yoshihide, Etoh, Takafumi, Fujita, Yasuyuki, Hashimoto, Takashi, Higashiyama, Mari, Igarashi, Atsuyuki, Ihn, Hironobu, Iwatsuki, Keiji, Kabashima, Kenji, Kawada, Akira, Kawashima, Makoto, Nakamura, Koichiro, Okubo, Yukari, Okuyama, Ryuhei, Ozawa, Akira, Sayama, Koji, Seishima, Mariko, Shiohara, Tetsuo, Takahara, Masakazu, Takahashi, Hidetoshi, Takehara, Kazuhiko, Tanese, Keiji, Tani, Mamori, Umezawa, Yoshinori, Watanabe, Hideaki, Yamanaka, Keiichi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412888/
https://ncbi.nlm.nih.gov/pubmed/27726163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.13622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados